Last reviewed · How we verify
Chlorhexidine gluconate at 0.125%
At a glance
| Generic name | Chlorhexidine gluconate at 0.125% |
|---|---|
| Sponsor | Universidad de Guanajuato |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Dentin Graft and I-PRF With and Without Vitamin C for Post-extraction Socket Preservation (NA)
- Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty (NA)
- Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures (PHASE4)
- Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine gluconate at 0.125% CI brief — competitive landscape report
- Chlorhexidine gluconate at 0.125% updates RSS · CI watch RSS
- Universidad de Guanajuato portfolio CI